RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy. (NCT05883631)
Prospective, Single Arm, Multi-center, Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-pulmonary Vein Sources of Atrial Fibrillation and Guide Ablation Therapy.
🩺 Plain-English Summary (8th-Grade Level)
Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and De Novo or Redo procedures. Phenotype patients and demonstrate the prognostication power of Electrographic Flow (EGF®) maps among all subjects using 12-month follow-up outcomes following EGF-guided mapping and ablation.
Who can join: Review the eligibility criteria below.
Location: University of Alabama — Birmingham, Alabama
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- University of Alabama — Birmingham, Alabama
- Grandview Medical Center — Birmingham, Alabama
- Banner Health — Phoenix, Arizona
- Sutter Health Sequoia Heart and Vascular Institute — Redwood City, California
- Pacific Heart Institute — Santa Monica, California
- Colorado Heart — Golden, Colorado
- Florida Heart Rhythm Specialists — Fort Lauderdale, Florida
- Ascension Medical Group — Jacksonville, Florida
- Piedmont Health — Athens, Georgia
- Beaumont Health — Royal Oak, Michigan
- Mount Sinai Hospital — New York, New York
- Ohio State University — Columbus, Ohio
- University of Virginia — Charlottesville, Virginia
- Inova Health — Falls Church, Virginia
- Evergreen Health Research/Overlake Medical Center — Bellevue, Washington
- OLV Hospital Aalst — Aalst,
- ZNA Middelheim — Antwerp,
- ZOL — Genk,
- Neuron Medical — Brno,
- IKEM (Institute for Clinical and Experimental Medicine) — Prague,
- Na Homolce Hospital — Prague,
- Amsterdam UMC (location AMC) — Amsterdam, North Holland
- St. Antonius Hospital — Nieuwegein, Utrecht
- Erasmus MC — Rotterdam,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atrial Fibrillation
- CHAMPION-AF Clinical Trial — Birmingham, Alabama
- Reversal of Atrial Substrate to Prevent Atrial — Calgary, Alberta
- Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients — Rochester, New York
- REView of ProcEdural FactoRs and Outcomes After Atrial Fibrillation Ablation With Active Esophageal COOLing: A Sub-Study of the REAL AF Registry — Chandler, Arizona
- Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF) — Cleveland, Ohio
- Liraglutide Effect in Atrial Fibrillation — Miami, Florida
Explore by condition: All Atrial Fibrillation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.